A recent study did demonstrate the value in optimizing the CD30 CAR co-stimulatory domain, as those CD30 CARs containing two co-stimulatory molecules (CD28 and OX40) were longer lived and had greater anti-tumor action [59]. Here, TNFRSF8 is linked to neoplasm.